Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2016

Open Access 01-12-2016 | Research article

Incidence of venous thromboembolism and hemorrhage related safety studies of preoperative anticoagulation therapy in hip fracture patients undergoing surgical treatment: a case–control study

Authors: Zhongdi Liu, Na Han, Hailin Xu, Zhongguo Fu, Dianying Zhang, Tianbing Wang, Baoguo Jiang

Published in: BMC Musculoskeletal Disorders | Issue 1/2016

Login to get access

Abstract

Background

Venous thromboembolism is a common postoperative complication following orthopedic surgeries, with morbid and potentially fatal consequences. Perioperative low-molecular-weight heparin (LMWH) therapy can reduce the incidence of venous thromboembolism, but may also increase the risk of bleeding complications. Current literature reflects the need to balance the improved efficacy of early initiating prophylaxis with increased risk of perioperative bleeding. The purpose of this study was to compare the effectiveness and hemorrhage related safety of preoperative versus postoperative LMWH therapy for prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in hip fracture patients.

Methods

We retrospectively evaluated 222 patients who underwent surgical treatment at Peking University People's Hospital between January 2009 and December 2010. Patients were allocated to two groups, receiving either preoperative or postoperative initiation of LMWH therapy for venous thromboembolism prophylaxis. Preoperative anticoagulation therapy was initiated 1–12 days prior to surgery (133 patients), and postoperative anticoagulation therapy was initiated 12 h after completion of surgery (89 patients). The preoperative group was further subdivided into four subgroups according to the time of initiation of therapy: 1–3 days before surgery (group A, 54 patients), 4–6 days before surgery (group B, 57 patients), 7–9 days before surgery (group C, 15 patients), and 10–12 days before surgery (group D, 7 patients). Occurrences of DVT, PE, adverse drug effects, intraoperative and postoperative bleeding were recorded, along with concentrations of preoperative and postoperative hemoglobin and length of hospital stay. The above parameters were compared between groups.

Results

Among recipients of preoperative anticoagulation therapy, two patients developed postoperative PE (1.5 %), one patient developed DVT (0.75 %). In the group receiving postoperative initiation of anticoagulation therapy, one patient each developed PE and DVT (1.1 %, 1.1 %). There was no difference in the occurrence of PE and DVT between the two groups (P>0.05, Chi-square tests). We identified the incidences of major bleeding, minor bleeding, and intraspinal hematoma after spinal anesthesia, which were 0 %/0 %, 3.76 %/3.37 %, and 0 %/0 %, respectively in preoperative and postoperative anticoagulation groups. There was no significant difference in the incidence of bleeding complications between patients receiving preoperatively initiated LMWH with patients receiving postoperatively initiated LMWH. Spinal anesthesia was administered to 168 patients, with no cases of postoperative intraspinal hematoma.

Conclusions

Preoperative anticoagulation therapy with LMWH may not increase intraoperative or postoperative blood loss, or the rate of intraspinal hematoma after spinal anesthesia, but also does not significantly reduce the risk of postoperative DVT or PE, compared to postoperative initiation.
Literature
1.
go back to reference Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S–453S.CrossRefPubMed Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S–453S.CrossRefPubMed
2.
go back to reference Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S–325S.CrossRefPubMedPubMedCentral Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S–325S.CrossRefPubMedPubMedCentral
3.
go back to reference Meza RG, Esquivel GR, Martinez DCSA, Espinosa-Larranaga F, Martinez GM, Torres GR, et al. Prophylaxis of venous thromboembolic disease in high-risk orthopedic surgery. Gac Med Mex. 2012;148(2):144–52. Meza RG, Esquivel GR, Martinez DCSA, Espinosa-Larranaga F, Martinez GM, Torres GR, et al. Prophylaxis of venous thromboembolic disease in high-risk orthopedic surgery. Gac Med Mex. 2012;148(2):144–52.
4.
go back to reference Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost. 2010;8(9):1966–75.CrossRefPubMed Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost. 2010;8(9):1966–75.CrossRefPubMed
5.
go back to reference Hull RD, Pineo GF, Stein PD, Mah AF, Macisaac SM, Dahl OE, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001;161(16):1952–60.CrossRefPubMed Hull RD, Pineo GF, Stein PD, Mah AF, Macisaac SM, Dahl OE, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001;161(16):1952–60.CrossRefPubMed
6.
go back to reference Perka C. Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. Thromb J. 2011;9:17.CrossRefPubMedPubMedCentral Perka C. Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. Thromb J. 2011;9:17.CrossRefPubMedPubMedCentral
7.
go back to reference Kalyani BS, Roberts CS. Low molecular weight heparin: current evidence for its application in orthopaedic surgery. Curr Vasc Pharmacol. 2011;9(1):19–23.CrossRefPubMed Kalyani BS, Roberts CS. Low molecular weight heparin: current evidence for its application in orthopaedic surgery. Curr Vasc Pharmacol. 2011;9(1):19–23.CrossRefPubMed
8.
go back to reference Hull RD, Pineo GF, Macisaac S. Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res. 2001;101(1):V155–62.CrossRefPubMed Hull RD, Pineo GF, Macisaac S. Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res. 2001;101(1):V155–62.CrossRefPubMed
9.
go back to reference Borgen PO, Dahl OE, Reikeras O. Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int. 2010;20(3):301–7.PubMed Borgen PO, Dahl OE, Reikeras O. Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int. 2010;20(3):301–7.PubMed
11.
go back to reference Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003;124(6 Suppl):379S–85S.CrossRefPubMed Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003;124(6 Suppl):379S–85S.CrossRefPubMed
12.
go back to reference Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H, et al. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost. 2003;90(4):654–61.PubMed Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H, et al. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost. 2003;90(4):654–61.PubMed
13.
go back to reference Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med. 2002;162(13):1451–6.CrossRefPubMed Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med. 2002;162(13):1451–6.CrossRefPubMed
14.
go back to reference Della RG, Biggi F, Grossi P, Imberti D, Landolfi R, Palareti G, et al. Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. Minerva Anestesiol. 2011;77(10):1003–10. Della RG, Biggi F, Grossi P, Imberti D, Landolfi R, Palareti G, et al. Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. Minerva Anestesiol. 2011;77(10):1003–10.
15.
go back to reference Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010;199(1 Suppl):S3–S10.CrossRefPubMed Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010;199(1 Suppl):S3–S10.CrossRefPubMed
16.
go back to reference Pedersen AB, Sorensen HT, Mehnert F, Overgaard S, Johnsen SP. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am. 2010;92(12):2156–64.CrossRefPubMed Pedersen AB, Sorensen HT, Mehnert F, Overgaard S, Johnsen SP. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am. 2010;92(12):2156–64.CrossRefPubMed
17.
go back to reference Jacobs JJ, Mont MA, Bozic KJ, Della VC, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746–7.CrossRefPubMedPubMedCentral Jacobs JJ, Mont MA, Bozic KJ, Della VC, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746–7.CrossRefPubMedPubMedCentral
18.
go back to reference Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res. 2001;101(1):V141–54.CrossRefPubMed Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res. 2001;101(1):V141–54.CrossRefPubMed
19.
go back to reference Rowlingson JC, Hanson PB. Neuraxial anesthesia and low-molecular-weight heparin prophylaxis in major orthopedic surgery in the wake of the latest American Society of Regional Anesthesia guidelines. Anesth Analg. 2005;100(5):1482–8.CrossRefPubMed Rowlingson JC, Hanson PB. Neuraxial anesthesia and low-molecular-weight heparin prophylaxis in major orthopedic surgery in the wake of the latest American Society of Regional Anesthesia guidelines. Anesth Analg. 2005;100(5):1482–8.CrossRefPubMed
20.
go back to reference Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.CrossRefPubMed Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.CrossRefPubMed
21.
go back to reference Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–98.CrossRefPubMed Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–98.CrossRefPubMed
22.
go back to reference Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3(12):2664–70.CrossRefPubMed Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3(12):2664–70.CrossRefPubMed
23.
go back to reference Warwick D. New concepts in orthopaedic thromboprophylaxis. J Bone Joint Surg (Br). 2004;86(6):788–92.CrossRef Warwick D. New concepts in orthopaedic thromboprophylaxis. J Bone Joint Surg (Br). 2004;86(6):788–92.CrossRef
24.
go back to reference Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999;159(2):137–41.CrossRefPubMed Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999;159(2):137–41.CrossRefPubMed
25.
go back to reference Kang BJ, Lee YK, Kim HJ, Ha YC, Koo KH. Deep venous thrombosis and pulmonary embolism are uncommon in East Asian patients after total hip arthroplasty. Clin Orthop Relat Res. 2011;469(12):3423–8.CrossRefPubMedPubMedCentral Kang BJ, Lee YK, Kim HJ, Ha YC, Koo KH. Deep venous thrombosis and pulmonary embolism are uncommon in East Asian patients after total hip arthroplasty. Clin Orthop Relat Res. 2011;469(12):3423–8.CrossRefPubMedPubMedCentral
26.
go back to reference Mont M, Jacobs J, Lieberman J, Parvizi J, Lachiewicz P, Johanson N, et al. Preventing venous thromboembolic disease in patients undergoing elective total hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):673–4.CrossRefPubMedPubMedCentral Mont M, Jacobs J, Lieberman J, Parvizi J, Lachiewicz P, Johanson N, et al. Preventing venous thromboembolic disease in patients undergoing elective total hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):673–4.CrossRefPubMedPubMedCentral
27.
go back to reference Warwick D, Rosencher N. The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis. Clin Appl Thromb Hemost. 2010;16(4):394–405.CrossRefPubMed Warwick D, Rosencher N. The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis. Clin Appl Thromb Hemost. 2010;16(4):394–405.CrossRefPubMed
28.
go back to reference Samama CM, Ravaud P, Parent F, Barre J, Mertl P, Mismetti P. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost. 2007;5(12):2360–7.CrossRefPubMed Samama CM, Ravaud P, Parent F, Barre J, Mertl P, Mismetti P. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost. 2007;5(12):2360–7.CrossRefPubMed
Metadata
Title
Incidence of venous thromboembolism and hemorrhage related safety studies of preoperative anticoagulation therapy in hip fracture patients undergoing surgical treatment: a case–control study
Authors
Zhongdi Liu
Na Han
Hailin Xu
Zhongguo Fu
Dianying Zhang
Tianbing Wang
Baoguo Jiang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2016
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-016-0917-y

Other articles of this Issue 1/2016

BMC Musculoskeletal Disorders 1/2016 Go to the issue